Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q53536137

about

Pathogenesis and disease mechanisms of occupational asthma What have transgenic and knockout animals taught us about respiratory disease?Th2 cytokines and asthma: an introduction Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs Therapeutic interventions in severe asthma Monoclonal antibodies and other biologic agents in the treatment of asthma Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation KB-Rank: efficient protein structure and functional annotation identification via text query A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease.IL-2-inducible T-cell kinase modulates TH2-mediated allergic airway inflammation by suppressing IFN-γ in naive CD4+ T cells.Recent advances: Respiratory medicine.Loss of regulator of G protein signaling 5 promotes airway hyperresponsiveness in the absence of allergic inflammation.Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines Biotherapeutic targets for the treatment of allergic airway disease.Type 1/Type 2 immunity in infectious diseases.Airway remodelling in asthma: from benchside to clinical practice.Gene-gene and gene-environmental interactions of childhood asthma: a multifactor dimension reduction approach.Drug treatment of airway inflammation in asthma.Cytokines and cytokine receptors in allergic rhinitis: how do they relate to the Th2 hypothesis in allergy?Targeting interleukin-4 in asthma: lost in translation?Exhaled markers of pulmonary disease.New insights into the role of cytokines in asthma Treatment strategies for bronchial asthma: an update.Molecular mechanisms of atopy Decreased prevalence of asthma among children with high exposure to cat allergen: relevance of the modified Th2 response New treatments for atopic dermatitis.Is Th1 the solution for Th2 in asthma?Soluble cytokine receptors in biological therapy.Treating the allergic patient: think globally, treat globally.New insights into the role of the mast cell in asthma.Management of asthma in adults: current therapy and future directions Drug development for asthma.Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.Biologic therapies targeting eosinophils: current status and future prospects.New targets for allergic rhinitis--a disease of civilization.Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models.Asthma refractory to glucocorticoids: the role of newer immunosuppressants.New strategies in the treatment and prevention of allergic diseases.

P2860

Q23924178-333EF88F-380E-49BF-B29B-11DB29882097 Q24791345-98F3B0D4-24EB-434D-A886-45E4840A0149 Q24791803-D3552702-F9DA-401E-97D7-C9ACED72F83C Q24791820-3DDBC3DC-1605-4A6E-9F1B-05D4C2066342 Q26786229-B9315776-BB04-4617-BE75-EFD6C9302BEE Q28067081-35E04FE3-F011-4300-9A64-CBAE0362D2E5 Q28079238-7A31F1FA-076D-4F05-BD6D-CC26BD541516 Q28270037-B38D0703-0C45-4C44-BDC6-65EEB059CA4D Q28534642-F7E66D0B-5A6E-498D-9B0F-4A08875E48AB Q28728482-DA52BCD3-4A17-4F09-8D88-F70BE225B2BE Q30406072-C9219106-2260-4B3C-8702-71FFB64AE688 Q33660094-0BC842B5-5D2D-41F1-9A55-70D7F1184DD3 Q33808282-01D291F5-B3FC-4872-B133-B8159C43F565 Q33993700-C9FF94E0-C79F-472D-85C3-F7ED1F665DBB Q34039588-E04CF9E4-847D-445E-8C60-09245CC25BED Q34058685-AF140333-1272-4B72-AF4A-5A40EF8EBF43 Q34105379-563EDFB0-6737-407D-A364-DF01FABC88DF Q34105688-CA4498DD-6A91-417C-B993-08A904F08D13 Q34166205-70842512-A4A1-46CE-8EF0-894F2235C497 Q34186818-C26B62CE-8042-4F7C-8726-A59FF48E9BC3 Q34190513-85C078F3-ACDB-4952-87BD-902362C7C9F7 Q34271232-5F58ACF2-30CD-40B5-813C-66944E2C6D94 Q34279117-BC37EF66-C44F-43C6-8255-453C7E4775EC Q34321721-2421E53C-ABBE-4D52-ADB2-5BC99C7B4A56 Q34342572-290C28C3-DFE7-47C6-A067-28B6BD007D82 Q34510796-20232C0D-AE27-4590-9773-02D5832B7A0D Q34510803-200AA893-14FF-4F4F-A0BB-15384C4FA251 Q34592295-AEAC741E-6830-4279-BFCC-3FA65A007CCD Q34632441-229FC8B0-2A73-4810-84F7-ED5B2D4465B7 Q34779777-A9B56C41-4D83-45F7-98DD-B46F3000E188 Q34881155-B7E47563-8D1B-4901-8A33-D2A654E43CFB Q35129653-1550459E-C656-4E25-9527-6CC00BB25F77 Q35143482-38347B39-29F6-410D-8F4A-32DDB316A5A2 Q35183997-580D1648-3BB5-4A82-9AFB-F39598616C75 Q35212261-3359C0AE-CF95-4671-A2A0-C1DCC16460BE Q35565533-A42BE1EB-CC1B-4921-BF7B-BD585C7403B9 Q35605442-A9D9CB30-F047-4F43-9680-77A8F1F0AB8F Q35627697-FE8EB5A4-5FBC-4E78-A8E3-DD1FB87DBB42 Q35627919-983E4C6F-E3F5-4309-A8AA-DC9A1076A143 Q35680646-BB9EF651-C4C6-40FD-A401-0343DD5124EA

P2860

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q53536137

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh-hant

name

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@en

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@nl

type

label

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@en

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@nl

prefLabel

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@en

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@nl

P1433

Q53536137-2794612D-63E5-4A10-ADAD-048E8F2E8D4D

P1476

Q53536137-1114312C-B570-47A8-AC18-4CF800EE469B

P2093

Q53536137-02F5237D-2B8D-41E7-BAFB-D61C3C631102

Q53536137-11AEB656-87C8-445F-AFA2-BC3CF99023A7

Q53536137-3B6E3244-51EF-429F-9A1A-796FF5D79867

Q53536137-674B9543-947B-49F7-AEDB-9B6512284199

Q53536137-C2BCBE0A-17A1-4248-9993-CA00C2B3EE43

Q53536137-F89D9E32-FB69-492A-ABE8-DD7AEC812597

P2860

Q53536137-006DCF27-FAF6-4FDC-9D9E-D2FCC4653FA7

Q53536137-01C89073-C6E2-4CAA-9F25-B32EE7FD49F9

Q53536137-051B887D-7791-4554-B1FC-A4A8585E1917

Q53536137-0B992122-0FF5-47B6-99CD-C686DFDFE155

Q53536137-0FB57AD4-8DAE-41E6-9ACB-5BC844CEE154

Q53536137-34F80100-C666-4168-85A8-CCF41AFA9B8D

Q53536137-3A0423F4-D900-4F48-ADE1-1A5EAAECE9F0

Q53536137-3BAFB273-D4BE-4465-83C6-18065E438DD7

Q53536137-6BBBE052-B0C9-46F3-903D-A92CB2F92823

Q53536137-7649F349-AA0F-42F2-B16E-EFB3E2DF1438

P304

Q53536137-7C8B3AC3-E27B-4F98-9336-3D099D66D323

P31

Q53536137-54C539EF-93C7-4BDD-97BD-E96E6FCF2172

P356

Q53536137-FCA1193D-C2E3-4210-A50B-F964ADA7D5DB

P407

Q53536137-94AE09CD-EA7C-4760-9E5C-B99138E9E0EA

P433

Q53536137-90FC8506-A1A0-4F60-957A-D0C96D55D1BB

P478

Q53536137-E248F908-C844-4AC5-ABA1-844E1DA90FCD

P50

Q53536137-FCA118F8-F676-4C83-B640-76DCF302A04E

P577

Q53536137-40B04B95-8547-44AB-AA0E-1B7FA6AE450D

P5875

Q53536137-145F4633-57FD-42F0-AA35-0DC5548CA74E

P698

Q53536137-9B8D5599-21AD-41E0-AF43-D70448FEBFB7

P921

Q53536137-1FAB5568-C08F-4E54-86D2-C8ABDDACF268

Q53536137-38fee3f9-9d47-4470-a0b0-0055b72c93d0

Q53536137-5932CB59-7542-49BD-830C-7474E170C7BA

Q53536137-85BCFDC3-ADB8-4456-9542-10CA8BD9994E

Q53536137-C28F7A36-94B4-43D7-B80D-D49525F5BC3F

P356

AJRCCM.160.6.9808146

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Interleukin-4 receptor in mode ...... zed, placebo-controlled trial.

@en

P2093

H S Nelson

http://www.w3.org/2001/XMLSchema#string

J B Whitmore

http://www.w3.org/2001/XMLSchema#string

J M Agosti

http://www.w3.org/2001/XMLSchema#string

L Claussen

http://www.w3.org/2001/XMLSchema#string

L Garrison

http://www.w3.org/2001/XMLSchema#string

M J Lanz

http://www.w3.org/2001/XMLSchema#string

P2860

Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily

Interleukin-13: central mediator of allergic asthma

The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.

Differential regulation of IgG1 and IgE synthesis by interleukin 4.

Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.

Osteoporosis induced in mice by overproduction of interleukin 4.

Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins

Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells.

Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice.

IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis.

P304

1816-1823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/AJRCCM.160.6.9808146

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

160

http://www.w3.org/2001/XMLSchema#string

P50

Larry C. Borish

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12711924

http://www.w3.org/2001/XMLSchema#string

P698

10588591

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial